Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 16/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 4/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28819251 | 0.82 | PKM (0.67) | PKMLMNAALDH1A1TSHRNPSR1 | |
| SCHEMBL30754639 | 0.82 | PKM (0.67) | PKMLMNAALDH1A1TSHRNPSR1 | |
| SCHEMBL2886915 | 0.81 | PKM (0.51) | PKMLMNAALDH1A1TSHRNPSR1 | |
| SCHEMBL18711517 | 0.80 | PKM (0.73) | PKMALDH1A1KMT2A | |
| SCHEMBL14314685 | 0.78 | PKM (0.65) | PKMLMNAALDH1A1TSHRNPSR1 | |
| SCHEMBL2888089 | 0.77 | PKM (0.63) | PKMLMNAALDH1A1TSHRNPSR1 | |
| SCHEMBL14314684 | 0.77 | PKM (0.63) | PKMLMNAALDH1A1TSHRNPSR1 | |
| SCHEMBL18701940 | 0.76 | PKM (0.67) | PKMALDH1A1KMT2A | |
| SCHEMBL14968229 | 0.76 | PKM (0.75) | PKMLMNAALDH1A1TSHRNPSR1 | |
| SCHEMBL10722317 | 0.74 | GAA (0.62) | PKMLMNAALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946227-B2 | Piperazine derivatives and methods of use | MERCK SERONO SA (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20130143893-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | MERCK SERONO SA (CH) | 2013-06-06 | — | — | US | disclosed |
| US-20100305137-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| US-7754722-B2 | Piperazine derivatives and methods of use | MERCK SERONO SA (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20060223813-A1 | Piperazine Derivatives and Methods of Use | MERCK SERONO SA (CH) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305137-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | CATSPER1, NASP, HDAC5 | PKM 1422/4885LMNA 2431/4885ALDH1A1 568/4885 |
| US-20130143893-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | CATSPER1, NASP, HDAC5 | PKM 1422/4885LMNA 2431/4885ALDH1A1 568/4885 |
| US-20060223813-A1 | Piperazine Derivatives and Methods of Use | CATSPER1, H1-5, GNRHR | PKM 2156/4885LMNA 1814/4885ALDH1A1 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.